Limited Edition Golden Llama is here! Check out how you can get one. 
Limited Edition Golden Llama is here! Check out how you can get one.
Offering SPR-BLI Services - Proteins provided for free! Offering SPR-BLI Services - Proteins provided for free!
Thank you for choosing ACROBiosystems. Would you rate our product and service？ Thank you for choosing ACROBiosystems. Would you rate our product and service？
Here come GMP Grade Cytokines！Free Sample is available！ Here come GMP Grade Cytokines！Free Sample is available！
5e5 of anti-MSLN CAR-293 cells were stained with 100 μL of 3 μg/mL of AF488-Labeled Human Mesothelin (296-580), His Tag (Cat. No. MSN-HA2H9) and negative control protein respectively (Fig. C and B), and non-transfected 293 cells were used as a control (Fig. A). AF488 signal was used to evaluate the binding activity (QC tested).
Anti-human MSLN mAb (chimeric mouse-human IgG1) captured on CM5 chip via Anti-human IgG Fc antibodies surface, can bind RFP Fusion Human Mesothelin (296-580), His Tag (Cat. No. MSN-HR2P4) with an affinity constant of 0.304 nM as determined in a SPR assay (Biacore T200) (Routinely tested).
Anti-human MSLN MAb (chimeric mouse-human IgG1) captured on CM5 chip via Anti-human IgG Fc antibodies surface, can bind GFP Fusion Human Mesothelin (296-580), His Tag (Cat. No. MSN-HG2P4) with an affinity constant of 0.542 nM as determined in a SPR assay (Biacore T200) (Routinely tested).
| Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
|---|---|---|---|---|---|
| RC-88 | RC-88 | Phase 2 Clinical | RemeGen Co Ltd | Solid tumours; Neoplasms; Carcinoma, Ovarian Epithelial; Peritoneal Neoplasms; Fallopian Tube Neoplasms | Details |
| iCasp9M28z | iCasp9M28z | Phase 2 Clinical | Memorial Sloan Kettering Cancer Center | Small Cell Lung Carcinoma; Pleural Diseases; Mesothelioma; Breast Neoplasms; Lung Neoplasms; Neoplasm Metastasis | Details |
| Anetumab ravtansine | BAY-94-9343; BAY-94-9343-SPDB-DM4; Anti-mesothelin antibody-drug conjugate BAY 94-9343 | Phase 2 Clinical | Bayer AG, Morphosys Ag | Ovarian Neoplasms; Solid tumours; Cystadenocarcinoma, Serous; Neoplasms; Pancreatic Neoplasms; Mesothelioma; Peritoneal Neoplasms; Fallopian Tube Neoplasms; Lung Neoplasms; Carcinoma, Endometrioid | Details |
| Gavocabtagene autoleucel | TC-210 | Phase 2 Clinical | Tcr2 Therapeutics Inc | Ovarian Neoplasms; Mesothelioma; Cholangiocarcinoma; Carcinoma, Non-Small-Cell Lung | Details |
| LMB-100 | LMB-100; RG-7787; RO-6927005 | Phase 2 Clinical | F. Hoffmann-La Roche Ltd | Neoplasms, Mesothelial; Carcinoma; Small Cell Lung Carcinoma; Adenocarcinoma of Lung; Neoplasms; Pancreatic Neoplasms; Mesothelioma; Cholangiocarcinoma; Lung Neoplasms; Pleural Effusion, Malignant; Carcinoma, Non-Small-Cell Lung | Details |
| anti-MESO CAR-T cells (Zhejiang University) | UCLM802; UCLM-802 | Phase 2 Clinical | Zhejiang University, Hrain Biotechnology Co Ltd | Ovarian Neoplasms; Solid tumours | Details |
| Anti-CTLA-4 and PD-1 CAR-T cell therapy (Shanghai Cell Therapy Research Institute) | Phase 2 Clinical | Shanghai Cell Therapy Research Institute | Neoplasms | Details | |
| HPN-536 | HPN-536 | Phase 2 Clinical | Harpoon Therapeutics | Neoplasms | Details |
| Autologous PD-1 antibody expressing mesothelin-targeted CAR-Tcells therapy (Shanghai Cell Therapy Research Institute) | Phase 2 Clinical | Shanghai Cell Therapy Research Institute | Solid tumours | Details | |
| CD40 ligand expressing MSLN-CAR T cells | Phase 2 Clinical | Pla General Hospital | Solid tumours | Details | |
| A2B-694 | A2B-694; A2B694 | Phase 2 Clinical | A2 Biotherapeutics Inc | Solid tumours; Ovarian Neoplasms; Rectal Neoplasms; Carcinoma, Renal Cell; Small Cell Lung Carcinoma; Colonic Neoplasms; Pancreatic Neoplasms; Neoplasms; Mesothelioma; Colorectal Neoplasms; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
| RNA-Meso-CIR-T | RNA-Meso-CIR-T | Phase 1 Clinical | Novartis Pharma Ag, University Of Pennsylvania | Mesothelioma | Details |
| CART-meso | CART-meso | Phase 1 Clinical | Novartis Pharma Ag, University Of Pennsylvania | Ovarian Neoplasms; Carcinoma; Adenocarcinoma of Lung; Carcinoma, Ovarian Epithelial; Pancreatic Neoplasms; Mesothelioma; Breast Neoplasms; Fallopian Tube Neoplasms | Details |
| ABBV-428 | ABBV-428; ABBV428 | Phase 1 Clinical | Abbvie Inc | Solid tumours | Details |
| Anti-mesothelin thorium-227 labeled antibody chelator conjugate | BAY-2287411 | Phase 1 Clinical | Bayer AG | Ovarian Neoplasms; Mesothelioma; Carcinoma, Pancreatic Ductal | Details |
| AB-1015 | AB-1015 | Phase 1 Clinical | Arsenal Biosciences Inc | Ovarian Neoplasms; Carcinoma, Ovarian Epithelial | Details |
| SynKIR-110 | SynKIR™-110; SynKIR-meso | Phase 1 Clinical | Verismo Therapeutics Inc | Ovarian Neoplasms; Mesothelioma; Cholangiocarcinoma | Details |
| KT-032 | KT-032 | Phase 1 Clinical | Nanjing Kati Medical Technology Co Ltd | Ovarian Neoplasms; Solid tumours; Pancreatic Neoplasms; Mesothelioma | Details |
| JNJ-79032421 | JNJ-79032421; JNJ-2421 | Phase 1 Clinical | Janssen Research & Development Llc | Solid tumours | Details |
| YL-215 | YL215; YL-215 | Phase 1 Clinical | MediLink Therapeutics Co Ltd | Solid tumours | Details |
| GPC3/Mesothelin-CAR-γδT Cells therapy(Second Affiliated Hospital Of Guangzhou Medical University) | Phase 1 Clinical | Second Affiliated Hospital Of Guangzhou Medical University | Solid tumours; Liver Neoplasms; Small Cell Lung Carcinoma; Pancreatic Neoplasms; Mesothelioma; Lung Neoplasms | Details | |
| AMG 305 | AMG-305; AMG 305 | Phase 1 Clinical | Amgen Inc | Solid tumours | Details |
| UCMYM-802 | UCMYM802; UCMYM-802 | Phase 1 Clinical | Shanghai Youti zjisheng Biomedicine Co Ltd | Solid tumours; Ovarian Neoplasms; Rectal Neoplasms; Pancreatic Neoplasms; Mesothelioma; Breast Neoplasms; Colorectal Neoplasms; Bile Duct Neoplasms | Details |
| HBM-9033 | HBM-9033; HBM9033 | Phase 1 Clinical | Nona Biosciences | Solid tumours | Details |
| Anti-mesothelin CAR T cell therapy (UTC Therapeutics Inc) | Phase 1 Clinical | UTC Therapeutics Inc | Solid tumours | Details | |
| LD013 CAR T-cell therapy (Nanjing Landun Biotechnology) | LD013; LD-013 | Phase 1 Clinical | Nanjing Landun Biotechnology Co Ltd | Ovarian Neoplasms; Solid tumours | Details |
| RD-138 | RD-138 | Phase 1 Clinical | Nanjing Iaso Biotherapeutics Co Ltd | Multiple Myeloma | Details |
| RD-133 | RD133 | Phase 1 Clinical | Nanjing Iaso Biotherapeutics Co Ltd | Solid tumours; Neoplasms | Details |
| PM-3006 | PM-3006 | Phase 1 Clinical | Biotheus Inc | Details | |
| Autologous Mesothelin-specific TCR-T Cell Therapy (Lonza Walkersville) | Phase 1 Clinical | Fred Hutchinson Cancer Research Center | Pancreatic Neoplasms; Carcinoma, Pancreatic Ductal | Details | |
| Anti-mesothelin CAR-NK cell therapy(Guojianchengnuo) | ALF-101 | Phase 1 Clinical | Guojianchengnuo Biotechnology (Beijing) Co Ltd | Carcinoma, Ovarian Epithelial | Details |
| Inezetamab | AMG-994 | Phase 1 Clinical | Amgen Inc | Solid tumours | Details |
| αPD1-MSLN-CAR T cell therapy (Shanghai Cell Therapy Group Co.,Ltd) | BZDS1901; BZDS-1901; BZD1901 | Phase 1 Clinical | Shanghai Cell Therapy Group Co Ltd | Ovarian Neoplasms; Solid tumours; Mesothelioma; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
| KD-021 | KD-021 | Phase 1 Clinical | Nanjing Kaedi Biotechnology Co Ltd | Neoplasms | Details |
| Anti-mesothelin CAR-T (Pregene) | Clinical | Pregene (Shenzhen) Biotechnology Co Ltd | Hydrothorax | Details | |
| TCR-like CAR-T Cell Therapy(Zhongda Hospital Southeast University) | Zhongda Hospital Southeast University | Details | |||
| Mesothelin-CAR-T Cells(Fapon Biopharma) | FP-002 | Fapon Biotech Inc | Details |
This web search service is supported by Google Inc.
アクロバイオシステムズの公式アカウント
A-Z
